PG002
Teriparatide biosimilar
Pipeline
Osteoporosis
Teriparatide
Teriparatide
Biosimilar
A bone formation promotor that solves the fundamental cause of osteoporosis
Features
Originator
A bone formation promotor that increases bone density by activating osteoblasts
Unlike general osteoporosis treatments that prevent bone decomposition, it’s a treatment that forms bone itself and is used for patients with severe osteoporosis
Teriparatide’s core mechanism of action
Teriparatide, made from the activated fragment of human parathyroid hormone (hPTH), is a bone formation promoter that can increase bone density by activating osteoblasts
Mechanism
Non-clinical study results
Confirmed increase in bone density similar to originator in osteoporosis induced rats
Equivalence analysis results
LC and MS analysis results show more than 99% physicochemical equivalence with the originatorAs a result of cAMP analysis using cell lines expressing hTPH receptor, intracellular changes were more than 99% similar when administered in the same manner as the originator
Teriparatide biosimilar research and development results
As a result of the development of a Teriparatide biosimilar, PEPGENE has completed the development of a biosimilar that is more than 99% similar to the originator